Iovance Shares Hits 52-Week High After Offering Pricing, FDA Approvals

By Dean Seal Shares of Iovance hit a 52-week high after the company's $211 million underwritten offering was priced and it announced key approvals from...

Related Keywords

,Drug Administration ,Wuxi Advanced Therapie Philadelphia ,Dean Seal ,Article Normal ,Regulation Government Policy ,New Products Services ,Product Service Approvals ,Corporate Industrial News ,Products Services ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Synd ,Regulation ,Government Policy ,New Products ,Services ,Product ,Service Approvals ,Corporate ,Industrial News ,Products ,